GENFIT: Leader of a €2.7M European-Funded EuroTransBio Program
[FR Version]
GENFIT to present at the BIO-Europe 2010 in Munich
GENFIT selected by Windhover for the 2011 Top Biopharma Projects to Watch
GFT505: A new clinical trial to consolidate its anti-diabetic potential
GFT505 potentiates insulin action in humans
GENFIT présent à Midcap Event à Paris les 20 et 21 septembre
GENFIT: €2.3 M participating development contract with OSEO
GENFIT: Annual General Meeting vote results
GENFIT announces its development plan for GFT505
GENFIT presents GFT505 results at the American Diabetes Association's 70th Scientific Sessions
GENFIT: Two major pre-diabetes clinical trials within the IT-Diab program
GENFIT: Milestone achieved as a compound developed in partnership enters the clinic
GENFIT to present at the 2010 Bio International Convention in Chicago
GENFIT to present at the Paris Smallcap Event on April 12 & 13
GENFIT : Règlement-livraison de l'augmentation de capital
GENFIT conforte sa structure financière en réalisant un placement privé de 2,3 millions d'euros
GENFIT obtains the renewal of the Oséo 'Innovative Company' Label and confirms its eligibility for FCPI mutual funds
GENFIT: GFT505 positioned as a leading drug candidate in its therapeutic area
[FR version]
GENFIT: Potential for combination of GFT505 with statins
GENFIT extends patent protection on GFT505 in major worldwide countries
